Are presepsin and resistin better markers for bacterial infection in patients with decompensated liver cirrhosis?


Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385

Informations de publication

Date de publication:
12 2019
Historique:
received: 10 01 2019
revised: 17 05 2019
accepted: 20 05 2019
pubmed: 22 6 2019
medline: 22 5 2020
entrez: 22 6 2019
Statut: ppublish

Résumé

Bacterial infections impair prognosis in patients with cirrhosis. Presepsin and, more recently, resistin are promising markers of infection and sepsis in patients without cirrhosis. The aim of our study was to assess the performance of presepsin and resistin as early markers of infection compared with C reactive protein (CRP) and procalcitonin (PCT), and their prognostic relevance in patients with decompensated cirrhosis. One hundred and fourteen consecutive patients with decompensated cirrhosis were enrolled and followed-up for 28 days. Diagnostic performances of CRP, PCT, presepsin and resistin were assessed. Fifty-three (46.5%) patients had bacterial infections of which 30 (56%) had sepsis. Presepsin and resistin had similar performance as CRP and PCT for the diagnosis of infection (best cut-off of 1444 pg/ml and 20 ng/ml, respectively) and sepsis. Presepsin (HR = 5.5; 95%CI: 2.36-13.21, p < 0.0001) and the ≥500 pg/ml increase of presepsin at 48 h (HR = 9.24; 95%CI: 3.66-23.27, p < 0.008) were independently associated with 28-day mortality. Presepsin and resistin have similar diagnostic performances to CRP and PCT for bacterial infection in decompensated cirrhosis. Presepsin and Δ presepsin ≥500 pg/ml have also a prognostic relevance for 28-day mortality.

Sections du résumé

BACKGROUND
Bacterial infections impair prognosis in patients with cirrhosis. Presepsin and, more recently, resistin are promising markers of infection and sepsis in patients without cirrhosis.
AIMS
The aim of our study was to assess the performance of presepsin and resistin as early markers of infection compared with C reactive protein (CRP) and procalcitonin (PCT), and their prognostic relevance in patients with decompensated cirrhosis.
METHODS
One hundred and fourteen consecutive patients with decompensated cirrhosis were enrolled and followed-up for 28 days. Diagnostic performances of CRP, PCT, presepsin and resistin were assessed.
RESULTS
Fifty-three (46.5%) patients had bacterial infections of which 30 (56%) had sepsis. Presepsin and resistin had similar performance as CRP and PCT for the diagnosis of infection (best cut-off of 1444 pg/ml and 20 ng/ml, respectively) and sepsis. Presepsin (HR = 5.5; 95%CI: 2.36-13.21, p < 0.0001) and the ≥500 pg/ml increase of presepsin at 48 h (HR = 9.24; 95%CI: 3.66-23.27, p < 0.008) were independently associated with 28-day mortality.
CONCLUSIONS
Presepsin and resistin have similar diagnostic performances to CRP and PCT for bacterial infection in decompensated cirrhosis. Presepsin and Δ presepsin ≥500 pg/ml have also a prognostic relevance for 28-day mortality.

Identifiants

pubmed: 31221548
pii: S1590-8658(19)30626-7
doi: 10.1016/j.dld.2019.05.025
pii:
doi:

Substances chimiques

Biomarkers 0
Lipopolysaccharide Receptors 0
Peptide Fragments 0
Procalcitonin 0
Resistin 0
presepsin protein, human 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1685-1691

Informations de copyright

Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Auteurs

Petra Fischer (P)

University of Medicine and Pharmacy "Iuliu Hatieganu", 3rd Medical Clinic, Hepatology Department, Cluj-Napoca, Romania.

Crina Grigoras (C)

University of Medicine and Pharmacy "Iuliu Hatieganu", 3rd Medical Clinic, Hepatology Department, Cluj-Napoca, Romania.

Anca Bugariu (A)

University of Medicine and Pharmacy "Iuliu Hatieganu", 3rd Medical Clinic, Hepatology Department, Cluj-Napoca, Romania.

Oana Nicoara-Farcau (O)

University of Medicine and Pharmacy "Iuliu Hatieganu", 3rd Medical Clinic, Hepatology Department, Cluj-Napoca, Romania.

Horia Stefanescu (H)

Regional Institute of Gastroenterology and Hepatology "Prof. Dr. Octavian Fodor", Hepatology Department, Cluj-Napoca, Romania.

Andreea Benea (A)

Regional Institute of Gastroenterology and Hepatology "Prof. Dr. Octavian Fodor", Hepatology Department, Cluj-Napoca, Romania.

Adina Hadade (A)

University of Medicine and Pharmacy "Iuliu Hatieganu", Department of Anesthesia and Intensive Care I, Cluj-Napoca, Romania.

Simona Margarit (S)

University of Medicine and Pharmacy "Iuliu Hatieganu", Department of Anesthesia and Intensive Care I, Cluj-Napoca, Romania.

Zeno Sparchez (Z)

University of Medicine and Pharmacy "Iuliu Hatieganu", 3rd Medical Clinic, Hepatology Department, Cluj-Napoca, Romania; Regional Institute of Gastroenterology and Hepatology "Prof. Dr. Octavian Fodor", Hepatology Department, Cluj-Napoca, Romania.

Marcel Tantau (M)

University of Medicine and Pharmacy "Iuliu Hatieganu", 3rd Medical Clinic, Hepatology Department, Cluj-Napoca, Romania; Regional Institute of Gastroenterology and Hepatology "Prof. Dr. Octavian Fodor", Hepatology Department, Cluj-Napoca, Romania.

Daniela Ionescu (D)

University of Medicine and Pharmacy "Iuliu Hatieganu", Department of Anesthesia and Intensive Care I, Cluj-Napoca, Romania; Outcome Research Consortium, Cleveland, USA.

Bogdan Procopet (B)

University of Medicine and Pharmacy "Iuliu Hatieganu", 3rd Medical Clinic, Hepatology Department, Cluj-Napoca, Romania; Regional Institute of Gastroenterology and Hepatology "Prof. Dr. Octavian Fodor", Hepatology Department, Cluj-Napoca, Romania. Electronic address: bogdan.procopet@umfcluj.ro.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH